Atherosclerosis coronary disease
Conditions
Interventions
Atherosclerosis
Chronic disease in childhood
Inflammation
Natural Killer T cells
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
12 Years to 64 Years
Inclusion criteria
Inclusion criteria: General criteria for all groups: * 12-19 years of age ;Obese adolescents: Definition according to the international standards of the International Obesity Task Force, see Cole et al, BMJ, 2000. ;JIA adolescents: * Polyarticular course JIA, including polyarticular JIA and extended oligoarticular JIA, rheumafactor negatieve. These patients often suffer from lifelong rheumatic disease, and are therefore at risk for early atherosclerosis. * More than 1 year after diagnosis. In first year of disease, patients undergo multiple study procedures, causing a burden on patients. In order to reduce the general burden, this study will focus on patients after their first year of disease. * BMI-SD
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: * Intoxication (smoking, drug-use) * Acute illness (fever) * Mental retardation * Claustrophobia * A history of allergic reactions to MR contrast fluids * Implanted electronic devices (i.e. pacemaker, internal cardioverter-defibrillator, cochlear implants, nerve- and bone stimulators) * Subjects with ferromagnetic clips in brain, eyes or lungs * A known reduced kidney function (GFR
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| iNKT cell numbers and function: numbers will be quantified by flow cytometry, function will be quantified by in vitro stimulation with iNKT cell ligands followed by quantitative PCR of iNKT cell cytokines. Early atherosclerosis: measured by cardiovascular magnetic resonance imaging (MRI), using aortic wall thickness and volume as the main readout. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary study parameters/endpoints 1) Markers of systemic inflammation: * multiplex immuno assay profiling of circulating inflammatory markers including cytokines and adipokines will be used to quantify circulating inflammatory mediators * phenotyping of circulating immune cell subtypes will be used to quantify circulating inflammatory cells 2) Cardiac ultrasonography markers for vascular dysfunction: * screening cardiac ultrasonography including left atrial volume and left ventricular volume and function * intima-media thickness measurement 3) Pulse wave velocity measurement for vascular dysfunction Other study parameters: 1) Anthropomorphic measurements: weight, length, BMI-SD, waist-hip ratio, fat percentage (bio-impedance measurement). 2) Growth: patients and their parents will be asked for permission (signed consent) to retrieve their growth charts from the GGD (gemeentelijke gezondheidsdienst, CB, schoolarts). 3) Nutrition: patients will be asked to complete a nutritional diary for 3 days, which takes 10 minutes a day. Standardized nutritional diaries are used for the cystic fibrosis adolescents already. 4) Medication use: descriptive data, will be derived from the patient information systems (Hix in WKZ/UMC Utrecht). 5) Metabolic profile: fasting glucose/insulin, HbA1c, lipid profile. 6) Physical activity: patients will be asked to fill in a questionnaire. The questionnaire is standardized and internationally published. The questionnaire is used by the child physical activity centre of the hospital already. | — |
Countries
The Netherlands
Outcome results
None listed